William E. Solander is a first-chair trial lawyer who represents pharmaceutical and other clients in high-stakes patent disputes, with particularly deep experience in Abbreviated New Drug Application (ANDA) litigation.
He has secured victories in a wide variety of forums, including federal district and appellate courts, the Patent Trial and Appeal Board (PTAB), and civil arbitrations. His experience includes prescription antiarrhythmic drugs, protein synthesis, new battery technologies, and prescription sleep aids.
Bill has developed significant knowledge of IP laws and civil justice systems outside the United States, and frequently counsels clients who seek strategic advice concerning business and legal activities outside the U.S. He has been on trial teams in Australia, Canada, Germany, Israel, and the United Kingdom, among other countries.
- Represented LEO Pharma against Tolmar Inc. and Perrigo Inc. on patents related to Taclonex, a topical anti-psoriatic medication
- Represented Sepracor Pharmaceuticals against Sandoz Inc., et al. on patents related to Clarinex®, an allergy medication
- Represented Sanofi in Sanofi v. Sandoz Inc., et al. on a patent related to Eloxatin®, a platinum-containing anti-cancer drug
- Represented Novartis Pharmaceuticals Corporation against Mylan Pharmaceuticals on a patent related to Femara®, an aromatase inhibitor
- Represented Sanofi and Bristol-Myers Squibb against Apotex, et al. on patents covering Plavix®, a leading anti-thrombotic agent
- Represented Novartis Pharmaceuticals Corporation against Dr. Reddy’s Laboratories Ltd. on patents covering Lamisil®, an anti-fungal medicine
- Represented Yamanouchi against Danbury Pharmacal on a patent related to Pepcid®, an anti-ulcer drug.
- J.D. Chicago Kent College of Law 1995
- B.S. California Polytechnic State University 1991
Bar Admissions : New York
Court Admissions :
- U.S. Court of Appeals for the Federal Circuit
- U.S. District Court for the Southern District of New York
Professional Memberships : Speaks and writes frequently on litigation strategy, polymorph patents, and Hatch-Waxman litigation.
Rate : $$$$